Patent Eligibility For Self-Learning Ai Systems In Biotechnology Research.
1. Overview: Patent Eligibility in AI and Biotechnology
The eligibility of patents is governed primarily by 35 U.S.C. § 101 in the United States, which allows patents for “any new and useful process, machine, manufacture, or composition of matter.”
For AI systems in biotechnology, the key challenges are:
Abstract Ideas: AI algorithms are often considered abstract, so they may not qualify unless tied to a concrete application.
Natural Phenomena / Laws of Nature: Biotech inventions often involve naturally occurring molecules or processes. AI that predicts or models these may be argued as abstract unless it demonstrates a practical application.
Inventive Concept: The AI system must provide a novel technical solution beyond conventional computing or lab methods.
2. Relevant US Case Laws
Case 1: Diamond v. Chakrabarty (1980)
Facts: The Supreme Court allowed a patent for a genetically engineered bacterium capable of breaking down crude oil.
Key Takeaways for AI in Biotech:
Living organisms can be patentable if human ingenuity creates something not naturally occurring.
Self-learning AI that designs or discovers novel genetically modified organisms or proteins could be patentable if the AI’s output is markedly different from natural processes.
Case 2: Mayo Collaborative Services v. Prometheus Laboratories (2012)
Facts: Mayo’s method claimed correlations between metabolite levels and drug efficacy, which the Supreme Court ruled unpatentable as it covered a natural law.
Implications for AI:
If AI predicts natural correlations (like gene-disease relationships) without adding inventive steps, it may be non-patentable.
To overcome this, AI systems must apply the predictions in a concrete, practical method, such as a novel drug screening process.
Case 3: Alice Corp. v. CLS Bank International (2014)
Facts: The Supreme Court held that merely implementing an abstract idea on a computer is not patentable.
Implications for AI:
Self-learning AI algorithms alone are likely abstract.
Patent eligibility is more likely when the AI is integrated into a specific biotechnology process, e.g., automated CRISPR design or protein folding simulations.
Case 4: In re Roslin Institute (Dolly the Sheep) (2006)
Facts: The U.S. PTO rejected a patent application for a cloned mammal, Dolly, arguing it was a product of nature.
Relevance to AI:
AI-derived biotech inventions must show human-directed modification.
If AI generates a new biological entity with properties not found in nature, it could qualify as patentable.
Case 5: Enfish, LLC v. Microsoft Corp. (2016)
Facts: The Federal Circuit ruled that a software invention can be patent-eligible if it improves computer functionality itself, rather than merely using a computer as a tool.
Relevance to AI in biotech:
If AI improves laboratory automation, genomic analysis, or molecular modeling efficiency, rather than just predicting outcomes, it strengthens patent eligibility.
Case 6: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals (2018)
Facts: A method for determining dosing of a drug based on genetic information was found patent-eligible because it applied a natural law in a practical method with specific steps.
Relevance for AI:
Self-learning AI that personalizes treatment or drug design based on genetic data could be patentable if it provides a practical, applied method rather than just an abstract model.
3. Key Considerations for AI Patents in Biotechnology
Specific Application: AI must be tied to a concrete biotech application (e.g., drug screening, gene editing, biomarker discovery).
Human Involvement / Inventive Step: AI-assisted inventions must demonstrate human-directed innovation.
Not Just Abstract Algorithms: AI learning models alone are usually insufficient.
Data and Output Novelty: Patents should focus on the novel outputs generated by AI (e.g., a new protein or therapeutic molecule).
4. Summary Table of Cases and Implications
| Case | Year | Key Principle | Relevance to AI Biotech |
|---|---|---|---|
| Diamond v. Chakrabarty | 1980 | Engineered life patentable | AI can create patentable biotech entities if human-directed |
| Mayo v. Prometheus | 2012 | Natural laws non-patentable | AI predictions of natural phenomena need practical application |
| Alice Corp v. CLS | 2014 | Abstract ideas not patentable | AI algorithms must be tied to concrete biotech processes |
| In re Roslin | 2006 | Cloned organisms non-patentable | AI must produce non-naturally occurring entities |
| Enfish v. Microsoft | 2016 | Software improving computer function patentable | AI improving biotech processes is more patentable |
| Vanda Pharmaceuticals | 2018 | Practical application of natural law patentable | AI for personalized medicine can be eligible |
5. Practical Strategy for Patent Drafting
Emphasize AI-human collaboration.
Focus on specific biotechnological application, not just the model.
Include novel outputs or engineered molecules as the invention, not just the process.
Describe technical improvements (e.g., lab efficiency, predictive accuracy, automation).
RELATED Blog
comments